Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 6:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–31 of 7 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Chronic Nonmalignant Pain Clear all

Completed Phase 3 Interventional

A One-year, Open-label Study to Assess the Safety and Effectiveness of Extended Release Tramadol HCl in the Treatment of Chronic, Non-malignant Pain.

NCT00347685

View directory record Official record

Conditions: Chronic Pain
Interventions: tramadol ER; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Gainesville, Florida

Source: ClinicalTrials.gov public record

Updated Jun 20, 2012 · Synced May 21, 2026, 6:54 PM EDT

Completed Phase 2 Interventional

Open Label, Safety Study of EN3270 in Patients With Moderate to Severe Non-malignant, Chronic Pain

NCT00485225

View directory record Official record

Conditions: Chronic, Non Malignant Pain
Interventions: EN3270; Drug
Lead sponsor: Durect; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Berlin, New Jersey

Source: ClinicalTrials.gov public record

Updated Feb 22, 2012 · Synced May 21, 2026, 6:54 PM EDT

Completed Phase 3 Interventional Results available

An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain

NCT00487435

View directory record Official record

Conditions: Pain, Osteoarthritis, Low Back Pain
Interventions: Tapentadol (CG5503) Extended Release (ER); Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older

Enrollment: 1,166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 118
States / cities: Birmingham, Alabama • Hoover, Alabama • Mobile, Alabama + 115 more

Source: ClinicalTrials.gov public record

Updated May 8, 2014 · Synced May 21, 2026, 6:54 PM EDT

Completed Phase 2 Interventional Results available

A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy

NCT01443403

View directory record Official record

Conditions: Opioid-induced Constipation
Interventions: Placebo, Naldemedine; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years and older

Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 49
States / cities: Phoenix, Arizona • Sun Lakes, Arizona • Little Rock, Arkansas + 46 more

Source: ClinicalTrials.gov public record

Updated Jun 25, 2017 · Synced May 21, 2026, 6:54 PM EDT

Terminated Phase 2 Interventional

Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain

NCT00278824

View directory record Official record

Conditions: Pain
Interventions: Matrix Transdermal Fentanyl/CHADD Drug Delivery System, Placebo Patch; Drug
Lead sponsor: ZARS Pharma Inc.; Industry
Eligibility: 18 Years to 70 Years

Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 15
States / cities: Phoenix, Arizona • Jacksonville, Florida • Marietta, Georgia + 12 more

Source: ClinicalTrials.gov public record

Updated Jun 4, 2012 · Synced May 21, 2026, 6:54 PM EDT

Completed Phase 3 Interventional

Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain

NCT00225797

View directory record Official record

Conditions: Chronic Pain
Interventions: Oxymorphone Extended Release; Drug
Lead sponsor: Endo Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 33
States / cities: Hueytown, Alabama • Phoenix, Arizona • Colorado Springs, Colorado + 27 more

Source: ClinicalTrials.gov public record

Updated Jan 1, 2024 · Synced May 21, 2026, 6:54 PM EDT

Completed Phase 3 Interventional Results available

A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain

NCT01186770

View directory record Official record

Conditions: Opioid-Induced Constipation
Interventions: Methylnaltrexone, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 804 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Raleigh, North Carolina

Source: ClinicalTrials.gov public record

Updated Sep 5, 2019 · Synced May 21, 2026, 6:54 PM EDT